secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2024-10-04T23:59:59+00:00
Accession:  0000950170-24-112887
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma amends SVB credit agreement, eliminates $20M cash reserve requirement
--------------------------------------------------------------------------------

- Second Amendment dated Oct 2, 2024 removes $20M minimum cash requirement from SVB loan agreement.
- New covenant requires Cue to maintain at SVB lesser of $20M or 100% of consolidated cash.
- No Event of Default occurred; representations and warranties reaffirmed as of effective date.
- All other terms of the Loan and Security Agreement remain unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000095017024112887/0000950170-24-112887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000095017024112887/cue-20241002.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-112887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer